Prostate Specific Antigen News and Research

RSS
GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Researchers develop PHI test to help determine aggressiveness of prostate cancer

Researchers develop PHI test to help determine aggressiveness of prostate cancer

Study reviews impact of focal therapy for low-risk prostate cancer patients

Study reviews impact of focal therapy for low-risk prostate cancer patients

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Screening rates for skin cancer low among middle-aged and older Caucasian adults: CINJ study

Screening rates for skin cancer low among middle-aged and older Caucasian adults: CINJ study

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Targeted therapy MDV3100 is effective for patients with CRPC: Study

Targeted therapy MDV3100 is effective for patients with CRPC: Study

PSA test distress, study urges caution

PSA test distress, study urges caution

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

U.Va. develops Prostate Exam Simulator

U.Va. develops Prostate Exam Simulator

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.